Novartis Insiders

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

Novartis employes about 109 K people. The company is managed by 56 executives with total tenure of roughly 334 years, averaging almost 5.0 years of service per executive having 1946.43 employees per reported executive. Discussion of Novartis management performance can provide insight into the enterprise performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Novartis AG future performance. Additionally, see Stocks Correlation.

Search Insiders

 
Refresh
  Chris Ilsley  CEO
President CEO
  Elizabeth Barrett  CEO
CEO, Novartis Oncology
  Daniel Vasella  Chairman
Honorary Chairman of the Board

  Return on Sales

Novartis Management Team Effectiveness

Novartis AG has Return on Asset of 0.0821 % which means that on every $100 spent on asset it made $0.0821 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.1782 % implying that it generated $0.1782 on every 100 dollars invested. Novartis management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Novartis Return on Invested Capital is relatively stable at the moment as compared to the last year. Novartis reported last year Return on Invested Capital of 0.25. As of 06/05/2020, Return on Sales is likely to grow to 0.30, while Return on Average Assets are likely to drop 0.0008. Novartis Total Assets are relatively stable at the moment as compared to the last year. Novartis reported last year Total Assets of 118.37 Billion. As of 06/05/2020, Assets Non Current is likely to grow to about 102 B, while Asset Turnover is likely to drop 0.37. Novartis Total Liabilities is relatively stable at the moment as compared to the last year. Novartis reported last year Total Liabilities of 62.82 Billion. As of 06/05/2020, Liabilities Non Current is likely to grow to about 35.6 B, while Current Liabilities is likely to drop slightly above 23.7 B. As of 06/05/2020, Weighted Average Shares is likely to drop to about 2.3 B. In addition to that, Issuance Purchase of Equity Shares is likely to drop to about (5.5 B)

Novartis Workforce Comparison

Novartis AG is regarded third in number of employees category among related companies. The total workforce of Drug Manufacturers?General industry is now estimated at about 691,793. Novartis retains roughly 109,000 in number of employees claiming about 16% of equities under Drug Manufacturers?General industry.

Novartis Profit Margins

The company has Net Profit Margin of 0.25 % which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 33.89 % which entails that for every 100 dollars of revenue it generated 0.34 of operating income.

Novartis AG Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Novartis AG Price Series Summation is a cross summation of Novartis price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Novartis Stakeholders

Chris Ilsley President CEO
Richard Saynor Chief Executive Officer of Sandoz, Member of the Executive Committee
Elizabeth Barrett CEO, Novartis Oncology
Francesco Balestrieri Chief Executive Officer of Sandoz, Member of the Executive Committee
Paul Hudson Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
Susanne Schaffert CEO Novartis Oncology, Member of the Executive Committee
Bruno Strigini CEO of Novartis Oncology, Member of the Executive Committee
Michael Ball CEO of Alcon, Member of the Executive Committee
Joseph Jimenez CEO, Member of the Executive Committee
Daniel Vasella Honorary Chairman of the Board
Joerg Reinhardt Independent Non-Executive Chairman of the Board
Enrico Vanni Independent Non-Executive Vice Chairman of the Board
Alex Krauer Honorary Chairman of the Board
Ulrich Lehner Vice Chairman of the Board of Directors, Non-Executive Director
Mark Fishman Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Andre Wyss Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
James Bradner President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Ton Buechner Non-Executive Independent Director
Pierre Landolt Member of the Board of Directors
Elizabeth Doherty Non-Executive Independent Director
Srikant Datar Non-Executive Independent Director
Dimitri Azar Non-Executive Independent Director
Frans Houten Non-Executive Independent Director
Nancy Andrews Non-Executive Independent Director
Andreas Planta Non-Executive Independent Director
Ann Fudge Non-Executive Independent Director
Verena Briner Non-Executive Independent Member of the Board
Steven Baert Chief People & Organization Officer, Member of the Executive Committee
Richard Francis Member of the Executive Committee and Division Head, Sandoz
Erwin Vanhaecke Head Novartis Group Quality
Charlotte PamerWieser Corporate Secretary
Shannon Klinger Chief Risk and Compliance Officer, Group General Counsel
Samir Shah Global Head Investor Relations
David Epstein Member of the Executive Committee, Division Head, Pharmaceuticals
MarieFrance Tschudin President of Novartis Pharmaceuticals, Member of the Executive Committee
Simon Moroney Director
Steffen Lang Global Head of Novartis Technical Operations, Member of the Executive Committee
Brian McNamara Member of the Management Board, Division Head, Novartis OTC
Andrews C Non-Executive Independent Director
Michele Galen Head Communications
Charles Sawyers Non-Executive Independent Member of the Board
John Tsai Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee
Bertrand Bodson Chief Digital Officer, Member of the Executive Committee
Robert Weltevreden Head of Novartis Business Services (NBS), Member of the Executive Committee
Vasant Narasimhan Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Jeffrey George Member of the Executive Committee and Division Head, Sandoz
Patrice Bula Non-Executive Independent Director
Peter Kornicker Chief Compliance Officer
William Winters Non-Executive Independent Member of the Board
George Gunn Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel Head of Corporate Strategy and External Affairs
Klaus Moosmayer Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee
Felix Ehrat General Counsel and General Counsel of Novartis International Ag
Andrin Oswald Member of the Executive Committee, Division Head, Vaccines and Diagnostics
Bridgette Heller Director

About Novartis Management Performance

The success or failure of an entity such as Novartis AG often depends on how effective the management is. Novartis management team is responsible for propelling the future growth in the right direction and for administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novartis management before purchasing its stock. It's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novartis management is utilizing all available resources in the best possible way? Also, how well is the company doing, relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity. Please read more on our stock advisor page.
Last ReportedProjected for 2020
Return on Average Assets 0.09  0.0008 
Return on Average Equity 0.17  0.0018 
Return on Invested Capital 0.25  0.26 
Return on Sales 0.29  0.30 
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 109000 people.

Novartis Manpower Efficiency

Return on Novartis Manpower

Revenue Per Employee446.6 K
Revenue Per Executive869.3 M
Net Income Per Employee65.5 K
Net Income Per Executive127.5 M
Additionally, see Stocks Correlation. Please also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page